跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 28,526 条关于
“Actuate-2401”
全部
28,526
临床试验
26,697
药物
1,316
机构
5
资讯
508
去年
Actuate Therapeutics' Elraglusib Shows Promise in Pancreatic Cancer as IPO Lock-up Expires
去年
Lipocine's LPCN 2401 Demonstrates Significant Body Composition Improvements in Obesity Study
3年前
Elraglusib Receives FDA Orphan Drug Designation for Pancreatic Cancer Treatment
去年
Actuate Therapeutics and Lantern Pharma Collaborate on AI-Driven Elraglusib Development
去年
Actuate Therapeutics Reports Significant Survival Improvement in Metastatic Pancreatic Cancer Phase 2 Trial
2年前
Actuate Therapeutics' Elraglusib Shows Promise in Relapsed/Refractory Ewing Sarcoma Trial
去年
Elraglusib Granted FDA Rare Pediatric Disease Designation for Ewing Sarcoma
去年
Actuate Therapeutics Raises $17.25 Million to Advance GSK-3β Inhibitor for Difficult-to-Treat Cancers
9个月前
Actuate Therapeutics Reports Positive Phase II Results for Elraglusib in Advanced Salivary Gland Cancers
去年
Elraglusib Receives EMA Orphan Drug Designation for Pancreatic Cancer Treatment
第 1 页,共 51 页
上一页
下一页